# Excretion of Rivaroxaban in Human Breast Milk

> **NCT06831474** · PHASE1 · RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 10 (estimated)

## Conditions studied

- Postpartum
- VTE Prophylaxis
- VTE (Venous Thromboembolism)
- Rivaroxaban
- Breastfeeding
- Breast Milk Collection

## Interventions

- **DRUG:** Rivaroxaban 10 MG Oral Tablet
- **DRUG:** Rivaroxaban 20 MG Oral Tablet

## Key facts

- **NCT ID:** NCT06831474
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-07-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831474, "Excretion of Rivaroxaban in Human Breast Milk". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06831474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*